Assessment and topographic characterization of locoregional recurrences in head and neck tumours by Ferreira, Brigida Costa et al.
Ferreira et al. Radiation Oncology  (2015) 10:41 
DOI 10.1186/s13014-015-0345-4RESEARCH Open AccessAssessment and topographic characterization of
locoregional recurrences in head and neck tumours
Brigida Costa Ferreira1,6*, Rui Vale Marques2, Leila Khouri2, Tânia Santos3, Pedro Sá-Couto4
and Maria do Carmo Lopes5Abstract
Purpose: To evaluate the differences between three methods of classification of recurrences in patients with head
and neck tumours treated with Radiation Therapy (RT).
Materials and methods: 367 patients with head and neck tumours were included in the study. Tumour
recurrences were delineated in the CT images taken during patient follow-up and deformable registration was used
to transfer this volume into the planning CT. The methods used to classify recurrences were: method CTV quantified
the intersection volume between the recurrence and the Clinical Target Volume (CTV); method TV quantified the
intersection between the Treated Volume and the recurrence (for method CTV and TV, recurrences were classified
in-field if more than 95% of their volume were inside the volume of interest, marginal if the intersection was
between 20-95% and outfield otherwise); and method COM was based on the position of the Centre Of Mass of the
recurrence. A dose assessment in the recurrence volume was also made.
Results: The 2-year Kaplan-Meier locoregional recurrence incidence was 10%. Tumour recurrences occurred in 22
patients in a mean time of 16.5 ± 9.4 months resulting in 28 recurrence volumes. The percentage of in-field recurrences
for methods CTV, TV and COM was 7%, 43% and 50%, respectively. Agreement between the three methods in
characterizing individually in-field and marginal recurrences was found only in six cases. Methods CTV and COM agreed
in 14. The percentage of outfield recurrences was 29% using all methods. For local recurrences (in-field or marginal to
gross disease) the average difference between the prescribed dose and D98% in the recurrence volume was -5.2 ± 3.5%
(range: -10.1%-0.9%).
Conclusions: The classification of in-field and marginal recurrences is very dependent on the method used to
characterize recurrences. Using methods TV and COM the largest percentage of tumour recurrences occurred in-field in
tissues irradiated with high doses.
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Dosimetric assessmentIntroduction
Intensity Modulated Radiation Therapy (IMRT) offers
significant improvements in treatment quality for head
and neck tumour cases especially in terms of toxicity
[1-3]. The steep dose gradients obtained with IMRT
dose distributions, compared with 3D conformal RT,
allows better target volume coverage and normal tissue
sparing. Accurate target volume delineation, combined* Correspondence: brigida@ua.pt
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becomes then crucial because uncertainties in structures
definition combined with deviations in patient positioning
relatively to the planned treatment may significantly affect
outcome.
With the technological developments in RT, informa-
tion about the patterns of failure of treatment tech-
niques currently in practice are fundamental to identify
the steps of the RT workflow where more aggressive
strategies or practice improvements may bring additional
therapeutic benefits. The steep penumbras of IMRT dose
distributions, aimed at protecting radiosensitive normal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics
Characteristic N (%)
Gender
Male 308 (83.9)
Female 59 (16.1)
Site
Larynx 84 (22.9)
Oral cavity 74 (20.2)
Oropharynx 70 (19.1)
Nasopharynx 45 (12.3)
Pharyngeal-laryngeal 38 (10.4)
Hypopharynx 27 (7.4)
Others 29 (7.9)
T stage
1-2 188 (51.8)
3-4 175 (48.2)
N stage
0-1 164 (45.2)
2-3 199 (54.8)
AJCC stage
I 37 (10.2)
II 34 (9.4)
III 69 (19.1)
IV 222 (61.3)
Type treatment
Post-operative 151 (41.1)
Definitive 216 (58.9)
RT Treatment technique
3DCRT 57 (15.5)
dIMRT 98 (26.7)
rIMRT 155 (42.2)
IMRT 57 (15.5)
3DCRT stands for 3D Conformal RT, dIMRT stands for forward optimized IMRT
(using 15-25 segments), rIMRT refers to inversely optimized IMRT planned with
a small number of segments (30-55 segments) while IMRT was planned with
about 70-80 segments.
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misses in target borders [4,5]. However, in previous stud-
ies the majority of locoregional treatment failures origi-
nated in regions irradiated with high doses and seldom
from the boundaries between the target volume and the
parotids, oral cavity or submandibular glands [6-8].
The criteria used to judge the type of recurrence is fun-
damental. Recurrences classified as in-field may indicate
the need for a dose escalation in the target volume. A high
incidence of marginal recurrences may suggest the need
to increase clinical and setup margins to account for un-
certainties in delineation and patient positioning, respect-
ively, provided that acceptable rates of complications are
still obtained. Alternatively, more sophisticated strategies
combining 3D Image Guided RT with Adaptive RT may
have to be implemented on a larger scale [9]. A high rate
of outfield recurrences would recommend a revision in
target volume definitions or other treatment modalities.
The most common method of classification of locore-
gional recurrences is based on the quantification of the
intersection between the volume of the recurrence and
the 95% prescription isodose [5,6,8,10]. This isodose sur-
face encompasses the treated volume or the tissues that
received the therapeutic dose. Therefore this treated re-
gion is more relevant for the evaluation of failure pat-
terns than delineated target volumes. Raktoe et al [7]
quantified the volume of intersection of the recurrence
volume with the initial target volume but proposed a
new method to categorize recurrences. The centre of
mass of the recurrence volume was used to define its
origin assuming an isotropic tumour growth. The loca-
tion of this centre of mass relatively to target margins
defined the recurrence type.
In alternative to geometric evaluation methods, the
analysis of the dose in the recurrence volume has also
been made [5,8,11]. For local recurrences, the tissues
where the recurrence later developed were irradiated with
more than 85% of the prescription dose. For regional re-
currences coverages of at least 52% of the prescribed dose
were obtained [5,8].
Using the patterns of failure of patients with head and
neck tumours treated with RT at the Portuguese Oncology
Institute of Coimbra Francisco Gentil (IPOCFG), the pur-
pose of this retrospective study was the characterization of
locoregional recurrences using the geometric methods
described above and to evaluate the disparity in the
classification of recurrences when different methods are
used. These results were also compared with a dosimet-
ric analysis.
Materials and methods
Patients and treatments
367 patients with head and neck tumours, treated at
IPOCFG from May 2007 to June 2013 were included inthe study. Palliative and re-irradiated patients were ex-
cluded. Patient and disease characteristics are summa-
rized in Table 1. Patient group was composed by 308
men and 59 women with a median age of 58.1 years
(range: 12-88 years). Mean follow-up time was 16.6 ±
12.2 months (range: 40 days-6.1 years). Tumour cases
were divided in larynx (22.9%), oral cavity (20.2%), oro-
pharynx (19.1%), nasopharynx (12.3%), pharyngeal-
laryngeal (10.4%), hypopharynx (7.4%) and others (7.9%).
Tumour stage was divided in I-II (19.6%) and III-IV
(80.4%). Definitive RT was offered to 58.9%.
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with a thermoplastic mask. A Computer Tomography
(CT) scan without contrast and with 1.5 or 3 mm slice
thickness was acquired for treatment planning. For se-
lected patients additional imaging, like positron emission
tomography and/or magnetic resonance imaging, was per-
formed for better target volume delineation. Target volume
delineation followed Grégoire et al [12] recommendation
for node negative neck and Grégoire et al [13] proposal for
CTV in node-positive and post-operative neck. Prescrip-
tion doses to primary tumour volume (CTV-T, post-
operative or definitive) and large adenopathies (CTV-N)
ranged from 59.4-70.2 Gy and to high and low risk lymph
nodes (CTV-N1 and CTV-N2, respectively) ranged from
50.4-59.4 Gy. Treatment planning objectives followed
ICRU 83 recommendations and planning evaluation
followed RTOG H-0022 [14,15]. 95% of the volume of the
PTVs should receive 95% of the prescribed dose and not
surpass 107%. A maximum dose constraint in the spinal
cord and brain stem of 45 Gy and 54 Gy, respectively, was
imposed. As objective, among others, the mean dose in the
parotids should be as low as possible aiming at achieving
less than 26 Gy [14]. The main organs at risk included
spinal cord, brainstem, parotid glands, thyroid, mandible
and others considered relevant for each pathology.
Simpler target volumes were irradiated with 3D Con-
formal Radiation Therapy (3DCRT) where up to 10
beams were sufficient to reach treatment goals. These
included 16% of the patients mostly with stage I-II tu-
mours of the larynx and oral cavity. More complex cases
were irradiated with IMRT. In 2006 forwardly optimized
IMRT (direct, dIMRT) was implemented and used until
2012. This technique used 5-7 gantry directions with a
total of 15-25 segments manually optimized. Dose frac-
tionation schedule was based in the delivery of five frac-
tions, of 1.8 Gy, per week delivered by two or three
sequential plans. This technique was progressively re-
placed by inversely optimized step and shoot IMRT since
2008 using 5-9 6MV photon beams (Oncor Avant-Garde
from Siemens) and 30-55 segments (rapid, rIMRT). In-
versely optimized step and shoot IMRT, using 5-9 beams
equidistant or angle optimized and an average of 70-80
segments (IMRT), was used when a smaller number of
segments was not sufficient and patient could sustain lon-
ger irradiation times. These were mostly nasopharynx, and
more complex oropharynx, hypopharynx and pharyngeal-
laryngeal cases. With inverse IMRT, dose integration of at
least two prescription dose levels was made [16].
The local protocol for Image Guided RT was followed
for patient positioning verification and replanning needs.
In summary, patient positioning was verified before
treatment in the first three fractions and then weekly
using two orthogonal 2D portal images for 3DCRT and
dIMRT while MV-CBCT for inverse IMRT was usedinstead. A tolerance action level for the difference be-
tween the patient and the machine isocenter of 3 mm was
adopted [17]. Furthermore, around the middle of RT or
when significant anatomic variations were observed, a sec-
ond CT was performed to evaluate differences in the dose
distribution compared to the planned dose. For this pa-
tient cohort, Adaptive RT was performed in 22 patients.
NCCN guidelines were adopted for patient follow-up.
The cumulative incidence of local and locoregional re-
currences were calculated using the Kaplan-Meier method
counting the first RT fraction as the starting day.
Classification of locoregional recurrences
Tumour recurrences were diagnosed in 22 patients and
diagnostic images could be retrieved for 21. Recurrences
were defined as the reappearance of the disease after
complete tumour response to the initial treatment proto-
col, i.e., absence of visible disease during a minimum
period of four months after the clinical evidence of
complete tumour remission. Patients with residual or per-
sistent disease after RT were not included in this study.
Tumour recurrences were delineated in the CT images
taken within the clinical follow-up protocol. Deformable
registration, using Velocity AI (version 2.8.1), was used
to co-register this CT set with the planning CT using
the local clinical protocol for image registration [18]. In
summary, a region of interest around the recurrence vol-
ume in the follow-up CT was defined as the image vol-
ume of interest to be deformed. First, a rigid registration
was made between the two sets of CT images followed
by deformable registration using the pre-defined filters
in Velocity AI. The recurrence structure was then trans-
ferred into the planning CT and clinical validation was
made by the radiation oncologist. This deformed struc-
ture is mentioned, in here, as the recurrence volume al-
beit it refers to the tissues inside that region in the
planning CT and not the recurrence itself. Geometric and
dosimetric analysis was made assuming that the point of
origin of the recurrence is an undetermined point within
this deformed recurrence volume where at least one clono-
genic cell survived radiation therapy. Repopulation of this
surviving clonogenic cell or cells generated the macroscopic
tumour volume, or recurrence, whose cells were in fact
never irradiated. Although algorithms for elastic deform-
ation still need to be biologically and physically validated,
these were used in this study as the elastic deformation be-
tween two sets of images of the same patient provides to-
day’s most accurate results.
Three methods were used to classify tumour recur-
rences. Method CTV quantified the intersection volume
between the recurrence and the Clinical Target Volume
(CTV). Method TV quantified the intersection between
the Treated Volume (TV, defined as the 95% isodose [19])
and the recurrence volume. Both for method CTV and
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of their volume were inside the volume of interest, mar-
ginal if the intersection was between 20-95% and outfield
otherwise. Method COM, as proposed by Raktoe et al [7],
was based on the position of the Centre Of Mass (COM)
of the deformed recurrence volume (recurrence structure
transferred into the planning CT), relatively to the nearest
target volume border, i.e., for local recurrences the target
volume corresponding to gross disease and for regional re-
currences elective target volumes. With this method re-
currences were defined as marginal when the minimum
distance between the centre of mass and the closest target
border was within ±3 mm. This tolerance accounts for un-
certainties in delineation, empirically estimated to be be-
tween 2-3mm, and registration deformation, quantified to
be between 3-5% or 1 mm [18]. Negative values indicate
that the centre of mass was found outside the planning
target volume and recurrence was defined as outfield
while a positive value classifies the recurrence as in-field.
Throughout this study recurrences were divided into
three main groups: local, regional and outfield. The motiv-
ation for this grouping was twofold. First, the probability of
treatment failure near gross disease may be different than
near microscopic disease. Therefore, there must be a clear
separation between local recurrences (associated to gross
disease, i.e., primary tumour and large adenopathies) from
regional recurrences (associated to spread of microscopic
disease, i.e., target volumes delineated to account for
lymphatic spread). Outfield recurrences should theoretic-
ally have an origin outside delineated target volumes and
therefore ideally should have no association with gross or
known patterns of microscopic disease. Second, the classi-
fication of recurrences using different methods was con-
sistent in the definition of outfield recurrences. However
there was a large disparity in the classification of in-field
and marginal recurrences which were clearly related to
local and regional recurrences. Thus local in-field or mar-
ginal recurrences will be referred as local; while regional
in-field or marginal as regional (triangles and circles, re-
spectively, in Figure 1 and Figure 2). Remaining cases will
be referred as outfield (squares in Figure 1 and Figure 2).
For the dosimetric analysis, the recurrence structure de-
formed into the planning CT was used to determine the
mean dose, the maximum significant dose (D2%) and the
minimum significant dose (D98%) [15] for the overall treat-
ment delivered to each patient. All plans initially planned
with pencil beam were re-calculated using collapsed-cone
algorithm (six patients). Dose distributions have been cor-
rected for incomplete treatment delivery (two cases).
Results
The 24 months Kaplan-Meier estimate for local and
locoregional recurrence was 7.4% and 10.3%, respectively
(Additional file 1: Figure S1). Tumour recurrences wereobserved in 22 patients (Table 2). Mean time for locore-
gional failure was 16.5 ± 9.4 months (range: 6.8-35.0
months). Most recurrences were found in patients with
high stage tumours: III-IV (81.8%). Most common primary
tumour site for recurrence events was: hypopharynx 5/27
(18.5%), oropharynx 5/70 (7.1%), oral cavity 5/74, larynx
4/84 (4.8%), nasopharynx 2/45 and pharyngeal-laryngeal
1/45. Recurrences were identified in 9/57 (9.2%) patients
irradiated with dIMRT, in 5/57 (8.8%) with 3DRCT, in 6
(3.9%) with rIMRT and in 2 (3.5%) irradiated with IMRT
(Table 2). Mean time for recurrence diagnosis was: for
dIMRT 20.8 ± 9.8 months, for 3DCRT 9.2 ± 2.4 months
and for rIMRT 13.2 ± 5.2 months.
Recurrences were classified as local to gross disease in
10 cases (closed triangles in Figure 1), local to the
tumour bed in three cases (open triangles) and regional
in seven cases (circles). Eight recurrences were classified
as outfield (squares). Only one recurrence occurred in
the vicinity of the parotid.
Consistency between the three methods in characteriz-
ing in-field and marginal recurrences was found in two
and four cases, respectively. Comparing method TV and
COM, consistency in classifying in-field and marginal re-
currences was found in 14 cases (values and symbols in
Figure 1, respectively). All methods were consistent in
the classification of the eight outfield recurrences.
Using method CTV, one and twelve recurrences were
considered in-field and marginal, respectively, to local dis-
ease; and one and six were considered in-field and mar-
ginal to regional target volumes, respectively (Table 3).
With method TV, ten and three were classified in-field
and marginal, respectively, to the highest dose level (pre-
scribed to gross disease). Two and five were considered
in-field and marginal, respectively, to lowest dose levels
prescribed to the lymph nodes (intersection volumes in
Figure 1).
In method COM, eleven, one and one were classified
as in-field, marginal and outfield to local disease, re-
spectively; three and four were classified as in-field and
marginal to regional volumes, respectively.
The symbols in Figure 1 show the distance from the
centre of mass of the recurrence volume to the nearest
CTV margin. The average distance, between the centre of
mass of the recurrence and the nearest target margin, for
local recurrences was 7.1 ± 4.5 mm (range: 0.0-17.4 mm)
and for regional recurrences was 4.9 ± 7.7 mm (range: -2.6-
18.3 mm). The average distance for the first four outfield
recurrences (#21-24) was -1.3 ± 0.3 cm (range: -1.5- -0.8
cm) and for the outfield recurrences #25-28 was -4.1 ± 2.2
cm (range: -7.4- -2.7 cm).
The average mean dose and average D98% in the recur-
rence volumes for each group are shown in Table 4. For
local recurrences (triangles in Figure 2), the average dif-
ference between the prescribed dose and the mean dose
Figure 1 Comparison between method COM and TV. Symbols in the figure show the results for the COM method. The values around the
symbols show the results of method TV (intersection volume in percentage). In/M Local refers to local recurrences that were classified either as
in-field or marginal depending on the classification method. Closed symbols show cases treated with definitive RT while for cases with open
symbols the treatment was post-operative. Recurrences were ordered by recurrence type, by definitive or post-operative, by prescribed dose and
finally by recurrence volume.
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average difference between the prescribed dose and D98%
was -5.2 ± 3.5% (range: -10.1-0.9%) and the average dif-
ference between D95% in the initial target volume and
D98% in the recurrence was -0.2 ± 3.7% (range: -5.4-
6.2%). For regional recurrences (circles in Figure 2), the
average difference between the prescribed dose and the
mean dose in the recurrence was 1.4 ± 7.9% (range: -9.3-Figure 2 Dosimetric analysis in the recurrence volume. Dosimetric com
prescribed dose and 95% of the prescribed dose (shown by the X and ,̶ re
vertical bars (range D98%-D2%).15.0%) and the average difference between the pre-
scribed dose and D98% in the recurrence was -17.9 ±
27.4% (range: -63.8-12.6%).
Discussion
In this retrospective study the locoregional patterns of fail-
ure for head and neck cancer patients irradiated at IPOCFG
were reported and the topographic characterization ofparison between the dose in the deformed recurrence volume, the
spectively). The dose range in the recurrence volume is shown by the
Table 2 Patient and treatment characteristics for the patients with recurrence
Primary tumour site Stage Type RT Type CH Dpresc/Gy/#fx Ddeliv CTV-T/Gy RT tech Recurrence location Diagn./months Rec vol./cm3
Oral cavity (tongue) III Adjuvant (Post-op) 59.1/30 59.0 3DCRT Mobile Tongue + Cervical 6.7 2.0 + 27.6
Oral cavity (mand. gingivae) IVA Adjuvant (Post-op) 59.4/31 58.7 dIMRT Mandibular gingivae 7.8 7.0
Oral cavity (tongue) IVA Adjuvant (Post-op) 59.0/31 59.8 dIMRT Cervical 9.0 27.1
Oral cavity (hard palate) IVA Concomitant Cisplatin 70.2/39 70.2 3DCRT Pharynx + Cervical 8.5 16.6 + 82.2
Oral cavity (max. gingivae) IVA Concomitant (Post-op) Cisplatin 64.8/36 65.3 rIMRT Maxillary gingivae 8.7 9.9
Oropharynx (tonsil) II Intensive 70.2/33 69.8 rIMRT Tonsil 22.8 clinical
Oropharynx (tonsil) IVA Adjuvant (Post-op) 59.4/33 57.0 (pb) dIMRT Base tongue 21.1 4.0
Oropharynx (base tongue) IVA Sequential TPF 69.3/33 69.2 rIMRT Base tongue 9.8 36.6
Oropharynx (base tongue) IVA Sequential TPF 70.2/39 68.1 (pb) dIMRT Cervical 31.2 17.1
Oropharynx (base tongue) IVA Concomitant Cisplatin 69.6/33 68.7 IMRT Tonsil + Cervical + Submandid. 7.3 0.4 + 0.5 + 2.7
Hypopharynx (pyriform sinus) IVA Concomitant (Post-op) Cisplatin 64.8/33 56.9/29* rIMRT Posterior wall + Cervical 9.8 10.3 + 24.1
Hypopharynx (posterior wall) IVA Intensive 69.0/33 68.0 rIMRT Cervical 15.4 0.6 + 1.0
Hypopharynx (pyriform sinus) IVA Sequential PF 70.2/39 67.7 (pb) dIMRT Cervical 26.7 0.3
Hypopharynx (pyriform sinus) IVA Sequential PF 70.2/39 70.1 rIMRT Pyriform sinus 9.6 8.0
Hypopharynx (pyriform sinus) IVB Sequential TPF 70.2/39 72.4 (pb) dIMRT Cervical 23.7 15.2
Larynx (glottis) I Intensive 66/33 65.9 3DCRT Larynx 12.4 14.8
Larynx (glottis) II Intensive 70.0/35 69.9 3DCRT Larynx 9.2 19.4
Larynx (supraglottis) IVA Concomitant Cisplatin 70.2/39 69.4 (pb) dIMRT Larynx 32.6 1.3
Larynx (supraglottis) IVA Concomitant (Post-op) Cisplatin 64.8/36 62.6/35* dIMRT Glottis 8.8 1.7
Nasopharynx IIB Intensive 70.2/39 69.4 rIMRT Cervical 16.0 2.7
Nasopharynx IVB Concomitant Cisplatin 70.2/33 75.9 (pb) IMRT Right orbit 34.4 11.9
Pharyngeal-laryngeal IVA Adjuvant (Post-op) 59.4/33 59.7 dIMRT Peritracheostomy + Cervical 25.5 0.5 + 44.0
Dpresc and Ddeliv is the prescribed dose and the mean dose delivered to the primary tumour corrected for incomplete treatment delivery and recalculated with the collapsed-cone dose algorithm.
*Failure to complete prescribed treatment, (pb) refers to the dose calculation algorithm used for treatment planning.
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Table 3 Classification of 20 out of the 28 recurrences
volumes using method CTV, TV and COM
Method In-field Marginal Outfield N
CTV-T (primary tumour) CTV 1 9 0 10
TV 8 2 0
COM 8 1 1
CTV-N
(large adenopathies)
CTV 0 3 0 3
TV 2 1 0
COM 3 0 0
CTV-N1
(high risk lymph nodes)
CTV 1 4 0 5
TV 2 3 0
COM 2 3 0
CTV-N2 (low risk
lymph nodes)
CTV 0 2 0 2
TV 0 2 0
COM 1 1 0
The remaining eight recurrences were classified as outfield by all
evaluation methods.
N is the number of cases in each category.
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probability of locoregional recurrences was 10%. Patients
with hypopharynx tumours had the worst disease outcome
with a recurrences incidence of 19% compared to 7% for
patients with tumours in oropharynx and oral cavity or 5%
for larynx and nasopharynx tumour cases. Although sur-
vival statistics are consistent with others [3,5], these should
be regarded with caution due to the short mean follow-
up time and the heterogeneity of the population varying
in terms of tumour type, stage, treatment protocol, RT
technique and fractionation. A deeper understanding
of the causes for treatment failure for each tumour
type and treatment technique is needed. However, the
number of recurrences was too small to allow taking
any further conclusions. Given the low incidence of
locoregional recurrences, the identification of the
localization of radioresistant malignant cells may be the
best therapeutic approach aiming to improve tumour
control without increasing the probability of complica-
tions to all patients.Table 4 Summary of the dose assessment for the recurrence
Type Group Vol ± SD/cm3 Presc
Local CTV-T (def.) 14.0 ± 14.4 70.2
CTV-T (post-op) 9.3 ± 12.8 59.4-6
CTV-N (3 cases) 1.4 ± 1.1 70.2
Regional CTV-N1 14.5 ± 18.0 54-59
CTV-N2 15.6 ± 16.3 50.4
Outfield 19.5 ± 26.8
Vol refers to the average volume of the recurrences for each group.
CTV-T stands for the clinical target volume of the primary tumour, CTV-N for large aden
Def stands for definitive RT and post-op to post-operative.Studies are consistent in pointing out the advantages
of IMRT in the treatment of head and neck cancer
[2,14]. Some initial concerns were highlighted about the
consequence that the IMRT steep dose gradients could
have in terms of the probability of tumour control [4,5].
In this study only one periparotid recurrence was ob-
served. For that patient, given the proximity of a large
adenopathy to the right parotid, priority was given to
target volume coverage. No attempt was made to spare
that structure that was irradiated with more than 56 Gy.
At the time of the last follow-up appointment, 43
months after RT, that patient had good response to
stimulation and was thus graded with G1 xerostomia.
For this population cohort a fair comparison in terms of
treatment technique could not be made due to a bias in
patient selection. The RT technique used for the treat-
ment of each patient is a consequence of both the evolu-
tion of techniques at IPOCFG and the therapeutic needs
of each particular case. Although the treatment techniques
with highest incidence of recurrences were dIMRT and
3DCRT, this was the group of patients with the longest
follow-up time. Still for this very small sample of patients,
the mean time for recurrence for dIMRT and rIMRT was
21 months and 13 months, respectively. A longer follow-
up time is needed to validate these findings.
Three methods were employed to categorize recur-
rences in RT of head and neck tumour cases. All
geometric methods were consistent in the classification
of around 29% of outfield recurrences. However, for
in-field and marginal recurrences, the classification of
each recurrence was highly dependent on the method of
evaluation used (Table 3). The percentage of in-field
recurrences using method CTV, TV and COM was 7%,
43% and 50%, respectively. Even that the methods do
not concur in their absolute evaluation, in relative terms
method TV and COM categorized most recurrences as
occurring in-field, as reported by others [6-8]. In-field
recurrences may be a consequence of residual disease
advocating for the need of a dose escalation. Despite the
short follow-up time, a low rate of locoregional recur-
rences was achieved and an escalation in prescriptionvolumes
D/Gy Dmean ± SD [min-max] D98% ± SD [min-max]
69.6 ± 2.4 [66.6 – 74.2] 65.5 ± 2.5 [63.1 – 70.8]
4.8 60.3 ± 4.6 [57.1 – 65.6] 58.4 ± 5.8 [54.8 – 65.1]
69.1 ± 0.8 [68.4 – 69.9] 66.6 ± 1.8 [64.7 – 68.3]
.4 57.9 ± 6.4 [52.2 – 68.3] 48.6 ± 16.8 [21.5 – 66.9]
50.4 ± 1.3 [49.4 – 51.3] 39.3 ± 10.2 [32.1 – 46.5]
31.4 ± 17.0 [8.9 – 54.6] 21.5 ± 20.3 [0.7 – 52.1]
opathies, CTV-N1 for high risk lymph nodes and CTV-N2 for low risk lymph nodes.
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cations for all patients. Therefore, radioresistant tumours
should be identified through imaging and biomolecular
and genetic assays in order to individualize and escalate
prescription doses for more difficult cases. Better target
volume delineation, based on different imaging modal-
ities, would also help reducing marginal recurrences and
help to identify distant ill nodes that may result in out-
field recurrences.
Method TV is more relevant than method CTV because
the evaluation is based on the volume that received a high
dose thus making the analysis more insensitive to target
volume delineation. Given today’s uncertainties associated
with target volume definition, methods of recurrence clas-
sification independent from target volume delineation are
preferable. The larger size of the treated volume, as de-
fined by the 95% prescription isodose, compared with the
volume of the CTV led to the reclassification of most re-
currences from marginal with method CTV into in-field
with method TV. The discrepancy in the results obtained
between the two methods is highly dependent on the non-
biologically based threshold value of the intersection vol-
ume used to separate in-field from marginal and marginal
from outfield recurrences, generally 95% and 20%, respect-
ively [10]. For the method CTV the upper threshold is
critical for the number of recurrences that would be classi-
fied as in-field while for method TV this percentage would
only slightly vary (Figure 1).
In this study outfield recurrences may have two differ-
ent causes of treatment failure. Planned dosimetry for
the patient cases that resulted in the first four outfield
recurrences (#21-24 Figure 2) showed that target volume
coverage, or irradiation technique, were adequate, i.e.,
more than 98% of the PTV was irradiated with 95% of
the dose (except for one case where D98% was 93% of
the prescribed dose aiming to spare the ipsilateral optical
nerve). Most probable causes for treatment failure in
these four cases may then have been: small clinical mar-
gins, uncertainties in patient positioning or treatment
interruption (two patients did interrupt radiation ther-
apy two and five days). These patients would have then
benefited from wider clinical or setup margins in the
spot where the recurrence developed. According to the
theoretic definition of less than 20% of intersection,
these four recurrences were classified as outfield when
conceptually they should have been more appropriately
classified as marginal. The second group of outfield re-
currences represents in fact true outfield events (#25-28
Figure 1 and Figure 2). Volumetric methods for recur-
rence classification are thus strongly dependent on the
recurrence volume upon diagnosis and pathways of
tumour growth and expansion.
The ideal method of classification of tumour recur-
rences would be based on the precise identification ofrecurrence origin. Geometric characterization of the re-
currences using method COM assumes that the centre of
mass of the recurrence volume represents its origin [7].
This method is a valid alternative to categorize recur-
rences, but it is only independent of the time of diagnosis
if tumour growth is in fact isotropic. Otherwise, as for
other methods, it depends as well on tumour size and the
patterns of spread of malignant cells. Using method COM,
14/28 recurrences were classified as in-field as the dis-
tance between the centre of mass and the target had posi-
tive values above the uncertainty associated to target
volume delineation and image registration (Figure 1). Five
recurrences were classified as marginal as this distance
was within ±3 mm [18]. This value was slightly smaller
than the one estimated by Raktoe et al [7] because their
analysis was based on rigid image registration. For the first
four outfield recurrences (#21-24), the maximum distance
between the centre of mass and target borders was -1.5
cm (Figure 1) and for the true outfield recurrences (#25-
28) maximum distance to cervical targets was -7.6 cm.
This was the case of a patient with a tumour in the oral
cavity prescribed with unilateral irradiation that relapsed
in the contralateral cervical lymph nodes (rec #28). For
the distances reported, the first group of outfield recur-
rences was probably caused by inaccuracies in target vol-
ume delineation. Broader margins applied to all patients
would result in an increase in the overall rate of complica-
tions. Therefore, the quality of radiation therapy may be
improved by better target volume delineation by refining
the usage of different imaging modalities. As well, the
starting points of the second group of outfield recurrences
most probably could only have been detected through
additional imaging.
Deformable co-registration between the planning CT
and the images acquired to diagnose the recurrence
allowed to assess the dose delivered to the tissues in-
cluded in the recurrence volume. For local recurrences,
the dosimetric analysis indicates that in at least one
point within the region where the recurrence later devel-
oped the dose was insufficient to eradicate all tumour
cells. Comparing the dose in the recurrence volume with
the prescribed dose: the mean dose in the recurrence vol-
ume was at least 97% of the prescribed dose, the minimum
significant dose was larger than 90% of the prescribed dose
and at least 95% of D95% (triangles in Figure 2 and Table 4).
As in any other dose statistics based on DVH, some care
is recommended in the interpretation of these values as in
that case the 3D spatial information is lost. A minimum
dose in the recurrence volume of 90% of the prescribed
dose may seem too low compared to ICRU recommenda-
tions, but corresponds to the worst case obtained. Further-
more, for all recurrences the minimum dose in its volume
was outside the initial target volume and distant from
its borders. Therefore, this difference may represent an
Ferreira et al. Radiation Oncology  (2015) 10:41 Page 9 of 9underestimation of the dose delivered at the recurrence
origin. If these recurrences are in fact a result of remaining
disease, the small deviation between the minimum dose
in local recurrences and the prescribed dose provides evi-
dences about the radioresistance of head and neck tumour
cases. A similar analysis for regional recurrences is not
that straightforward because the dose range in this volume
increases significantly as recurrences grows outside the
target volume (Figure 2).
Conclusions
For RT of head and neck cancers at our institution a
low rate of locoregional recurrences was found. The
classification of in-field and marginal recurrences is very
dependent on the geometric method used for analysis
because those rely on the recurrence volume upon diag-
nosis and pathways of tumour growth. Nevertheless with
method TV and method COM the same general conclu-
sions were taken in categorizing most of the recurrences
as in-field. The dosimetric analysis supports the need
to identify patients with radioresistant tumours aiming
to individualize dose prescription.
Additional file
Additional file 1: Figure S1. Kaplan-Meier estimates for the cumulative
incidence of locoregional recurrence.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BCF wrote the manuscript after scientific discussions with RVM, LK and MCL.
RVM and LK delineated all regions of interest. BCF and TS carried out data
collection and quantitative analysis. PSC performed all statistical analysis.
All authors read and approved the final manuscript.
Acknowledgments
This work was financed by the Foundation for Science in Portugal with the
program PEst-C/CTM/LA0025/2011. P.Sá-Couto’s work was supported by
Portuguese funds through the CIDMA - Center for Research and Development
in Mathematics and Applications, and the Portuguese Foundation for Science
within project PEst-OE/MAT/UI4106/2014.
Author details
1I3N Physics Department, Aveiro University, Aveiro, Portugal. 2Radiation
Therapy Department, Portuguese Oncology Institute of Coimbra Francisco
Gentil (IPOCFG), Coimbra, Portugal. 3Physics Department, Coimbra University,
Coimbra, Portugal. 4Center for Research and Development in Mathematics
and Applications and Department of Mathematics, Aveiro University, Aveiro,
Portugal. 5Medical Physics Department, Portuguese Oncology Institute of
Coimbra Francisco Gentil, Coimbra, Portugal. 6Serviço de Física Médica, Inst.
Port. Oncology of Coimbra, Av. Bissaya Barreto 3000-075, Coimbra, Portugal.
Received: 16 June 2014 Accepted: 1 February 2015
References
1. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ. How does intensity-modulated
radiotherapy versus conventional two-dimensional radiotherapy influence the
treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol
Phys. 2011;80(3):661–8.2. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al.
PARSPORT trial management group. Parotid-sparing intensity modulated
versus conventional radiotherapy in head and neck cancer (PARSPORT): a
phase 3 multicentre randomised controlled trial. Lancet Oncol.
2011;12(2):127–36.
3. Toledano I, Graff P, Serre A, Boisselier P, Bensadoun RJ, Ortholan C, et al.
Intensity-modulated radiotherapy in head and neck cancer: results of the
prospective study GORTEC 2004-03. Radiother Oncol. 2012;103(1):57–62.
4. Cannon DM, Lee NY. Recurrence in region of spared parotid gland after
definitive intensity-modulated radiotherapy for head and neck cancer. Int J
Radiat Oncol Biol Phys. 2008;70(3):660–5.
5. Gupta T, Jain S, Agarwal JP, Ghosh-Laskar S, Phurailatpam R, Pai-Shetty R,
et al. Prospective assessment of patterns of failure after high-precision
definitive (chemo)radiation in head-and-neck squamous cell carcinoma.
Int J Radiat Oncol Biol Phys. 2011;80(2):522–31.
6. Chajon E, Lafond C, Louvel G, Castelli J, Williaume D, Henry O, et al. Salivary
gland-sparing other than parotid-sparing in definitive head-and-neck
intensity-modulated radiotherapy does not seem to jeopardize local control.
Radiat Oncol. 2013;8(1):132.
7. Raktoe SA, Dehnad H, Raaijmakers CP, Braunius W, Terhaard CH. Origin of
tumor recurrence after intensity modulated radiation therapy for
oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys.
2013;85(1):136–41.
8. Shakam A, Scrimger R, Liu D, Mohamed M, Parliament M, Field GC, et al.
Dose-volume analysis of locoregional recurrences in head and neck IMRT, as
determined by deformable registration: a prospective multi-institutional trial.
Radiother Oncol. 2011;99(2):101–7.
9. Yang H, Hu W, Wang W, Chen P, Ding W, Luo W. Replanning during
intensity modulated radiation therapy improved quality of life in patients
with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys.
2013;85(1):47–54.
10. Dawson LA, Anzai Y, Marsh L, Martel MK, Paulino A, Ship JA, et al. Patterns
of local-regional recurrence following parotid-sparing conformal and
segmental intensity-modulated radiotherapy for head and neck cancer. Int J
Radiat Oncol Biol Phys. 2000;46(5):1117–26.
11. Chao KS, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of failure
in patients receiving definitive and postoperative IMRT for head-and-neck
cancer. Int J Radiat Oncol Biol Phys. 2003;55(2):312–21.
12. Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, et al.
CT-based delineation of lymph node levels and related CTVs in the
node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus
guidelines. Radiother Oncol. 2003;69(3):227–36.
13. Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation
of the nodal CTV in the node-positive and the post-operative neck.
Radiother Oncol. 2006;79(1):15–20.
14. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and
function relationships in parotid salivary glands following conformal and
intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol
Biol Phys. 1999;45(3):577–87.
15. International Commission on Radiation Measurements, ICRU Report 83.
Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam
Therapy. Bethesda: ICRU Publications; 2010.
16. Ferreira BC, Lopes MC, Mateus J, Capela M, Mavroidis P. Radiobiological
evaluation of forward and inverse IMRT using different fractionations for
head and neck tumours. Radiat Oncol. 2010;5:57.
17. Wang J, Bai S, Chen N, Xu F, Jiang X, Li Y, et al. The clinical feasibility and
effect of online cone beam computer tomography-guided intensity-
modulated radiotherapy for nasopharyngeal cancer. Radiother Oncol.
2009;90(2):221–7.
18. Lopes MC, Ferreira BC, Mateus J, Ventura T. Deformable image registration
for radiation therapy planning using Velocity AI software. Radiother Oncol.
2013;106(S2):S483.
19. International Commission on Radiation Measurements, ICRU Report 50.
Prescribing, recording, and reporting photon beam therapy, 50. Bethesda,
MD: ICRU Publications; 1994.
